30 closest matches · ranked by relevance
Death · Congestive Heart Failure
Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…
Heart Failure
Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants
Heart Failure
Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL
Sudden Cardiac Death · Sudden Cardiac Arrest · Heart Failure
Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants
Heart Failure, Diastolic
Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine
Acute Decompensated Heart Failure
Primary: Total Urine Sodium Output — 1082; 423 mmol of sodium — p=<0.001
Heart Failure
Primary: Post-treatment Urine Output as Measured by Cumulative Urine Output Within 1 Day. — 34.0; 29.8; 22.6; 30.1 mL/mg
Heart Failure · Depression
Primary: Beck Depression Inventory II — 9.3; 9.2; 9.0; 8.6 units on a scale — p=0.90
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Acute Decompensated Heart Failure · Volume Overload
Primary: Successful Decongestion — 79; 108 Participants
Heart Failure
Primary: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure — 889; 828 Participants…
Acute Decompensated Heart Failure
Primary: Short Physical Performance Battery (SPPB) at Month 3 — 6.9; 8.3 score on a scale — p=<0.0001
Heart Failure Acute · Heart Failure，Congestive · Heart Failure; With Decompensation
Primary: Dyspnea — 1264; 1650 mmxh — p=0.18
Heart Failure
Primary: Win Ratio of Composite Endpoint — 228; 206 Number of Wins for the group
Heart Failure
Primary: Acetazolamide Arm: Natriuresis 24 h — 324; 300; 211; 190 mmol — p=0.515
Heart Failure
Primary: Patient Well Being, as Determined by a Visual Analog Scale — 4236; 4372.7; 4170.8; 4429.6 units on a scale
Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary: Time-averaged Proportional Change in NT proBNP From Baseline to Weeks 4 and 8 — 0.7200; 0.8425 Geometric Mean Ratio — p=0.0492
Congestive Heart Failure
Primary: Change in Body Weight at 48 Hours — -3.3; -0.8 pounds — p=0.094
Acute Heart Failure
Primary: Overall Safety of a Strategy Based on Subcutaneous Delivery of Furosemide in Inpatients and Outpatients as Measured by Number of Adverse Events — 4; 9; 16; 11 participants
Heart Failure
Primary: 6 Minute Walk Test — 224; 247 meters
Heart Failure
Primary: Bioelectrical Impedance Change — 47.52; 47.1; 41.27; 46.8 Percentage of Extra Cellular Fluid
Heart Failure · Diabetes Mellitus, Type 2
Primary: Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight — -0.31; -0.42 kg/40mg IV furosemide
Heart Failure
Primary: Healthcare Utilization Costs — 2920.30; 7512.30 US Dollars — p=<0.0001
Congestive Heart Failure · Cardiomyopathy · Dyspnea
Primary: Number of Subjects With at Least 30 Days of Daily Impedance Measurements — 47; 106 participants
Heart Failure · Sleep Apnea Syndromes
Primary: Reduction in Episodic Oxygen Desaturation
Heart Failure, Diastolic · Obesity
Primary: Exercise Capacity — 15.5; 15.5; 14.1; 16.6 ml/kg/min — p=<0.001
Heart Failure With Reduced Ejection Fraction
Primary: Percentage of Patients Achieving the Target Dose of LCZ696 200 mg Bid at 10 Weeks Post Randomization — 224; 248 Participants — p=0.099
Diastolic Heart Failure
Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade
Heart Failure · Diabetes
Primary: Effect of Thiamine Supplementation on Dyspnea — 34; 32 mm
Heart Failure · Dyspnea
Primary: Dyspnea Improvement Measured by Likert Scale at 8 and 24 Hours — 20; 26 Participants — p=0.315